The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: The eleven-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

Arthritis and Rheumatism

Volumn 60, Issue 5, 2009, Pages 1222-1231

  Rantalaiho, Vappu ^a   Korpela, Markku ^a   Hannonen, Pekka ^b   Kautiainen, Hannu ^c   Järvenpää, Salme ^d   Leirisalo Repo, Marjatta ^e   Hakala, Markku ^f,j   Puolakka, Kari ^g   Julkunen, Heikki ^h   Luosuj̈arvi, Riitta ^e   Möttönen, Timo ⁱ  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^c ORTON Foundation   (Finland)

^d Medcare Foundation   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^g Lappeenranta Central Hospital   (Finland)

^h PEIJAS HOSPITAL   (Finland)

ⁱ TURKU UNIVERSITY HOSPITAL   (Finland)

^j TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEOPLASM; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; SULFASALAZINE; TREATMENT OUTCOME;

EID: 66049150438     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24447     Document Type: Article

References (36)

1. Kirwan JR. Links between radiological change, disability, and pathology in rheumatoid arthritis. J Rheumatol 2001;28:881-886 (Pubitemid 32246966)
2. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007;46:350-357
3. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-318
4. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, for the FIN-RACo Trial Group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353: 1568-1573
5. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-3390 (Pubitemid 41612204)
6. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443
7. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
8. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al, for the TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a doubleblind, randomized trial. Arthritis Rheum 2006;54:1063-1074
9. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-356
10. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo- Repo M, Hakala M, et al, for the FIN-RACo Trial Group. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-2081
11. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al, for the FIN-RACo Trial Group. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50:55-62.
12. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al, for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: fiveyear experience from the FIN-RACo trial. Arthritis Rheum 2005; 52:36-41.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
14. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol Suppl 1990;22: 12-15
15. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-145 (Pubitemid 10164318)
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
17. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-2024
18. Pinals RS, Masi AT, Larsen RA, Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-1315
19. Van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 2000;59 Suppl 1:i28-31.
20. Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year followup. Br Med J 1973;2:96-100.
21. Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32:717-723 (Pubitemid 23249179)
22. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42:1854-1860.
23. Jantti JK, Kaarela K, Belt EA, Kautiainen HJ. Incidence of severe outcome in rheumatoid arthritis during 20 years. J Rheumatol 2002;29:688-692 (Pubitemid 34303861)
24. Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002;61: 1055-1059 (Pubitemid 35397350)
25. Scott DL, Strand V. The effects of disease-modifying antirheumatic drugs on the Health Assessment Questionnaire score: lessons from the leflunomide clinical trials database. Rheumatology (Oxford) 2002;41:899-909.
26. Sokka T, Mottonen T, Hannonen P. Disease-modifying antirheumatic drug use according to the 'sawtooth' treatment strategy improves the functional outcome in rheumatoid arthritis: results of a long-term followup study with review of the literature. Rheumatology (Oxford) 2000;39:34-42.
27. Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 2003;115:371-376
28. Makinen H, Kautiainen H, Hannonen P, Sokka T. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria: a 5-year followup study. J Rheumatol 2005;32:796-800. (Pubitemid 40676485)
29. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-134
30. Sokka T, Mottonen T, Hannonen P. Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years. Scand J Rheumatol 1999;28:282-287
31. Kroot EJ, van Leeuwen MA, van Rijswijk MH, Prevoo ML, van 't Hof MA, van de Putte LB, et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of followup from disease onset. Ann Rheum Dis 2000;59:954-958
32. Cush JJ. Early rheumatoid arthritis - is there a window of opportunity? J Rheumatol Suppl 2007;80:1-7.
33. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-269
34. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, et al, and the CIMESTRA Study Group. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, doubleblind, parallel-group, placebo-controlled study. Arthritis Rheum 2006;54:1401-1409
35. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying antirheumatic-drugs in early rheumatoid arthritis: second year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008;67:815-822
36. Sokka T, Hakkinen A, Kautiainen H, Maillefert JF, Toloza S, Mork Hansen T, et al, on behalf of the QUEST-RA Group. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum 2008;59:42-50.